But, not quite unblinded and not quite too late?

Quote:

---

But, not quite unblinded and not quite too late?

---

Given the time it took for the 50% analysis it might have been between 0 days and a week between the end of analysis and end of trial. The crux of the problem with the trial was the skew in over 65 year old patients towards leronlimab. Is that a problem the DSMC would have even looked at? It sure wasn't noticed at the 50% interim analysis.